Axsome Therapeutics Financial Statements (AXSM)
|
|
Report date
|
|
|
01.03.2021 |
01.03.2022 |
31.12.2022 |
28.02.2023 |
23.02.2024 |
|
12.11.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
50.0 |
270.6 |
|
338.5 |
Operating Income, bln rub |
|
|
-99.1 |
-124.7 |
-179.8 |
-176.5 |
-231.8 |
|
-307.5 |
EBITDA, bln rub |
? |
|
-99.1 |
-123.6 |
-179.8 |
-174.2 |
-225.0 |
|
-300.6 |
Net profit, bln rub |
? |
|
-105.4 |
-134.9 |
-187.1 |
-197.8 |
-239.2 |
|
-311.0 |
|
OCF, bln rub |
? |
|
-78.5 |
-108.2 |
|
-116.5 |
-145.1 |
|
-132.6 |
CAPEX, bln rub |
? |
|
0.046 |
0.308 |
|
0.702 |
0.582 |
|
0.307 |
FCF, bln rub |
? |
|
-78.5 |
-108.5 |
|
-117.2 |
-145.7 |
|
-132.6 |
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
|
0.000 |
0.000 |
|
0.000 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
OPEX, bln rub |
|
|
99.1 |
124.7 |
229.8 |
221.3 |
476.4 |
|
620.0 |
Cost of production, bln rub |
|
|
0.078 |
1.16 |
5.20 |
5.20 |
26.1 |
|
32.0 |
R&D, bln rub |
|
|
70.2 |
58.1 |
57.9 |
57.9 |
97.9 |
|
162.6 |
Interest expenses, bln rub |
|
|
2.57 |
5.70 |
7.33 |
7.33 |
6.45 |
|
5.06 |
|
Assets, bln rub |
|
|
186.1 |
-338.4 |
331.5 |
331.5 |
588.2 |
|
561.5 |
Net Assets, bln rub |
? |
|
-278.8 |
-409.2 |
109.6 |
109.6 |
191.0 |
|
92.9 |
Debt, bln rub |
|
|
50.1 |
49.7 |
94.7 |
94.7 |
186.4 |
|
192.3 |
Cash, bln rub |
|
|
183.9 |
86.5 |
0.000 |
200.8 |
386.2 |
|
327.3 |
Net debt, bln rub |
|
|
-133.8 |
-36.8 |
94.7 |
-106.2 |
-199.8 |
|
-135.0 |
|
Ordinary share price, rub |
|
|
81.5 |
37.8 |
77.1 |
77.1 |
79.6 |
|
64.4 |
Number of ordinary shares, mln |
|
|
37.2 |
37.6 |
40.7 |
40.7 |
45.4 |
|
48.1 |
|
Market cap, bln rub |
|
|
3 031 |
1 421 |
3 136 |
3 136 |
3 615 |
|
3 101 |
EV, bln rub |
? |
|
2 897 |
1 384 |
3 230 |
3 030 |
3 416 |
|
2 966 |
Book value, bln rub |
|
|
-279 |
-409 |
40 |
40 |
126 |
|
32 |
|
EPS, rub |
? |
|
-2.83 |
-3.59 |
-4.60 |
-4.86 |
-5.27 |
|
-6.46 |
FCF/share, rub |
|
|
-2.11 |
-2.89 |
0.00 |
-2.88 |
-3.21 |
|
-2.75 |
BV/share, rub |
|
|
-7.49 |
-10.9 |
0.97 |
0.97 |
2.77 |
|
0.67 |
|
EBITDA margin, % |
? |
|
|
|
|
-348.2% |
-83.1% |
|
-88.8% |
Net margin, % |
? |
|
|
|
|
-395.2% |
-88.4% |
|
-91.9% |
FCF yield, % |
? |
|
-2.59% |
-7.64% |
0.00% |
-3.74% |
-4.03% |
|
-4.28% |
ROE, % |
? |
|
37.8% |
33.0% |
-170.8% |
-180.5% |
-125.3% |
|
-334.7% |
ROA, % |
? |
|
-56.6% |
39.9% |
-56.5% |
-59.7% |
-40.7% |
|
-55.4% |
|
P/E |
? |
|
-28.8 |
-10.5 |
-16.8 |
-15.9 |
-15.1 |
|
-9.97 |
P/FCF |
|
|
-38.6 |
-13.1 |
|
-26.8 |
-24.8 |
|
-23.4 |
P/S |
? |
|
|
|
|
62.7 |
13.4 |
|
9.16 |
P/BV |
? |
|
-10.9 |
-3.47 |
79.2 |
79.2 |
28.8 |
|
95.8 |
EV/EBITDA |
? |
|
-29.2 |
-11.2 |
-18.0 |
-17.4 |
-15.2 |
|
-9.87 |
Debt/EBITDA |
|
|
1.35 |
0.30 |
-0.53 |
0.61 |
0.89 |
|
0.45 |
|
R&D/CAPEX, % |
|
|
153 068% |
18 879% |
|
8 253% |
16 829% |
|
52 975% |
|
CAPEX/Revenue, % |
|
|
|
|
|
1.40% |
0.22% |
|
0.09% |
|
Axsome Therapeutics shareholders |